Merck & Co’s Januvia, the first DPP4 inhibitor, may grab over half of the $6 billion U.S. market for this new type of diabetes drugs, following the unveiling of positive research results. Januvia sales are forecast to double this year

Two articles published in the Journal of the American Medical Association (JAMA) have brought attention to Merck & Co.’s role regarding how their painkiller Vioxx was approved and remained on the market. JAMA alleges Merck drafted research studies and recruited experts to ghostwrite the reports. A second article suggests the drugmaker selected the data about mortality risks. Merck emphatically denies the allegations. Further details.

FDA’s sluggish response in removing Bayer’s Trasylol from the market took a heavy toll on the lives of 22,000 patients, renowned researcher tells CBS Television’s 60 Minutes program